The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
Anticardiolipin Antibodies Predict Early Recurrence of Thromboembolism and Death Among Patients with Venous Thromboembolism Following Anticoagulant Therapy
Abstract
Purpose To compare the risk of recurrent venous thromboembolism in patients with and without antiphospholipid antibodies.Patients and methods Anticardiolipin antibodies were tested 6 months after a first or second episode of venous thromboembolism. Of the patients with a first episode of venous thromboembolism only the 412 who received 6 months of anticoagulation were studied. Two hundred and eleven patients with a second episode received oral anticoagulation for 6 months or indefinitely. The therapy was targeted at an international normalized ratio (INR) of 2.0 to 2.85. All patients were followed up for 4 years after enrollment.Results Among the 412 patients with a first episode of venous thromboembolism the risk of recurrence was 29% in patients with anticardiolipin antibodies and 14% in those without antibodies (P = 0.0013). In those with antibodies, there was an increased risk during the first 6 months after cessation of anticoagulation. The risk of recurrence increased with the titer of the antibodies. Four-year mortality rate was 15% in those with antibodies and 6% in those without (P = 0.01). Among 34 patients with a second event of venous thromboembolism and anticardiolipin antibodies, there were no recurrences during anticoagulant therapy versus 20% in those who received only 6 months of treatment (P = 0.08).Conclusions The presence of elevated titers of anticardiolipin antibodies 6 months after an episode of venous thromboembolism is a predictor for an increased risk of recurrence and of death. Patients with anticardiolipin antibodies and venous thromboembolism seem to benefit from prolonged oral anticoagulation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Use of long-term anticoagulation in patients with APS is supported by two small direct comparison studies (one RCT, one retrospective cohort)28 29 that showed a lower risk of recurrent venous thrombosis among patients with APS on long-term vs 3–6 months of oral anticoagulation.”
From EULAR recommendations for the management of antiphospholipid syndrome in adults (2019) · cites this paper as [28]
Citations
Cites
The management of thrombosis in the antiphospholipid-antibody syndrome
Khamashta, M. A., Cuadrado, M. J., Mujic, F., Taub, N. A., Hunt, B. J., & Hughes, G. R. V. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321504 · Cited by 1,450
Schulman, S., Rhedin, A.-S., Lindmarker, P., Carlsson, A., Lärfars, G., Nicol, P., Loogna, E., Svensson, E., Ljungberg, B., Walter, H., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506223322501 · Cited by 932
Self-citationAntiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients
Rosove, M. H., & Brewer, P. M. C. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-4-303 · Cited by 700
The Duration of Oral Anticoagulant Therapy after a Second Episode of Venous Thromboembolism
Schulman, S., Granqvist, S., Holmström, M., Carlsson, A., Lindmarker, P., Nicol, P., Eklund, S. ‐., Nordlander, S., Lärfars, G., Leijd, B., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199702063360601 · Cited by 595
Self-citationAnticardiolipin Antibodies and the Risk for Ischemic Stroke and Venous Thrombosis
Ginsburg, K. S., Liang, M. H., Newcomer, L., Goldhaber, S. Z., Schur, P. H., Hennekens, C. H., & Stampfer, M. J. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-12-997 · Cited by 526
Vianna, J. L., Khamashta, M. A., Ordi, J., Font, J. A., Cervera, R., López‐Soto, A., Tolosa, C., Franz, J. K., Selva-O’Callaghan, A., Ingelmo, M., et al. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90108-2 · Cited by 466
Antiphospholipid Antibodies and venous thromboembolism
Ginsberg, J., Wells, P., Brill-Edwards, P., Donovan, D., Moffatt, K., Johnston, M., Stevens, P., & Hirsh, J. (1995) · Blood · doi:10.1182/blood.v86.10.3685.bloodjournal86103685 · Cited by 365
Hamsten, A., Björkholm, M., Norberg, R., Fairé, U. D., & Holm, G. (1986) · The Lancet · doi:10.1016/s0140-6736(86)92258-0 · Cited by 356
LACTATE AS ENERGY SOURCE FOR BRAIN IN GLUCOSE-6-PHOSPHATASE DEFICIENT CHILD
Fernandes, J., Berger, R. M. F., & Smit, G. (1982) · The Lancet · doi:10.1016/s0140-6736(82)90257-4 · Cited by 319
Derksen, R. H. W. M., de Groot, P. G., Kater, L., & Nieuwenhuis, H. K. (1993) · Annals of the Rheumatic Diseases · doi:10.1136/ard.52.9.689 · Cited by 240
Research works printed but not linked: 2
- Harris EN, Chan JKH, Asherson RA, et al. IgG anticardiolipin antibody (ACAG): possible predictor for thrombosis, thrombocytopenia and recurrent abortion. Arthritis Rheum 1985;28:S38. Abstract.
- 1993, Thrombosis and thrombocytopenia in antiphospholipid syndrome (idiopathic and secondary to SLE), Haematologica, 78, 313
Cited by
Sorted by citations
Items 401–493 of 493
Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism
Tran, H. A., McRae, S. J., & Ginsberg, J. S. (2006) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2005.09.004 · Cited by 1
Vrotniakaite-Bajerciene, K., Wang, T., Sabri, E., Shorr, R., Angelillo‐Scherrer, A., Gal, G. L., & Carrier, M. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026020623 · Cited by 1
McRae, S. J. (2011) · Springer eBooks · doi:10.1007/978-3-032-19328-5_10 · Cited by 1
Chapter 19 Future of the Antiphospholipid Syndrome
Kasthuri, R. S., & Roubey, R. A. S. (2009) · Technical report · doi:10.1016/s1571-5078(08)00419-4 · Cited by 1
Smikle, M., Wharfe, G., Fletcher, H. M., Reid, M. E., Roye-Green, K. J., Fredrick, J., & Pierangeli, S. S. (2003) · Human Antibodies · doi:10.3233/hab-2003-12302 · Cited by 1
The Case Against Routine Screening for Thrombophilia
Nicolaides, A. N. (2010) · Disease-a-Month · doi:10.1016/j.disamonth.2010.06.008 · Cited by 1
Best, I. M., Vasandani, G., Bumpers, H. L., & Rust, G. S. (2002) · Heart & Lung · doi:10.1067/mhl.2002.120566 · Cited by 1
Recent advances in pathogenesis and pathophysiology in the antiphospholipid syndrome
Horita, T. (2012) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.35.481 · Cited by 1
Hypertension artérielle pulmonaire et connectivites
HACHULLA, E., & Humbert, M. J. C. (2007) · Revue du Rhumatisme · doi:10.1016/j.rhum.2007.05.007 · Cited by 1
Long-term therapy of pulmonary embolism.
Agnelli, G., & Becattini, C. (2005) · PubMed · Cited by 1
Durée optimale du traitement anticoagulant au décours d’une embolie pulmonaire
Tromeur, C., & Couturaud, F. (2015) · La Presse Médicale · doi:10.1016/j.lpm.2015.07.005 · Cited by 1
Anticoagulation in the Perioperative Period
Suwanawiboon, B., & Ortel, T. L. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-2296-9.00037-3 · Cited by 1
Varfarin v terapii antifosfolipidnogo sindroma
Reshetnyak, T. M., Kondrateva, L., Shtivelband, I. B., & Nasonov, E. L. (2008) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2008-469 · Cited by 1
Herrera, R. N., Díaz, E. I., Aguilar, R. C. P., Bianchi, J., Berman, S., & Luciardi, H. L. (2005) · REMERI - Red Mexicana de Repositorios Institucionales · Cited by 1
Molecular aspects in clinical hemostasis research at Karolinska Institutet
Blombäck, M. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.03.095 · Cited by 1
Task Force Report on the Management of Thrombosis in Antiphospholipid Syndrome
Ruiz‐Irastorza, G., Pengo, V., Tektonidou, M. G., Ruiz‐Arruza, I., Cuadrado, M. J., & Khamashta, M. A. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3194-7_11 · Cited by 1
Long term use of anticoagulant therapy for patients with pulmonary embolism
Becattini, C., & Cimini, L. A. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1770589 · Cited by 1
Byambajav, T., Waki, T., Miura, K., & Tanaka‐Mizuno, S. (2021) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5343 · Cited by 1
Laboratory thrombophilia screening: essentials for hematologists
Kyrle, P. A. (2021) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-021-00769-3 · Cited by 1
López‐Candales, A., & Vallurupalli, S. (2021) · Springer eBooks · doi:10.1007/978-3-030-78255-9_14 · Cited by 1
Cáliz, R., Fontecha, P. D. D. C., Galindo-Izquierdo, M., Longo, F. J. L., Zamora, M. Á. M., Santamaría, A., Pliego, O. A., Lozano, M. J. C., Beltrán, M. P. D., Ortells, L. C., et al. (2019) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2018.11.012 · Cited by 1
Schürch, K. A., Holy, E. W., Kucher, N., & Barco, S. (2022) · Praxis · doi:10.1024/1661-8157/a003949 · Cited by 1
Should we be targeting type 1 interferons in antiphospholipid syndrome?
Santos, G. D. M., Saldanha, A., & Orsi, F. A. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109754 · Cited by 1
Chaston, R. (2006) · VCU Scholars Compass (Virginia Commonwealth University) · doi:10.25772/98ew-dv40 · Cited by 1
Antiphospholipid Syndrome in the Older Population
Pierangeli, S. S., Seif, A. M., & González, E. B. (2011) · Springer eBooks · doi:10.1007/978-1-4419-5792-4_24 · Cited by 1
VENOUS THROMBOEMBOLISM IN SOUTHERN SWEDEN EPIDEMIOLOGY AND RISK FACTORS
Isma, N. (2012) · Lund University Publications (Lund University) · Cited by 1
Extension of anticoagulation after venous thromboembolism
Schulman, S. (2008) · Hämostaseologie · doi:10.1055/s-0037-1617168 · Cited by 1
Self-citationSíndrome de Hughes y trombosis: el debate continúa
Ruiz‐Irastorza, G., & Khamashta, M. A. (2002) · Medicina Clínica · doi:10.1016/s0025-7753(02)72297-5 · Cited by 1
Durée du traitement anticoagulant oral dans la TVP des membres inférieurs
Pinède, L. (2002) · Annales de Cardiologie et d Angéiologie · doi:10.1016/s0003-3928(02)00089-6 · Cited by 1
Thrombosis in the antiphospholipid syndrome.
Küçükkaya, R. D. (2006) · PubMed · Cited by 1
(2013) · Springer eBooks · doi:10.1007/978-3-642-28753-4_102451 · Cited by 1
Pulmonary Hypertension and Antiphospholipid Antibodies
Pietté, J. C., & Hunt, B. J. (2006) · Springer eBooks · doi:10.1007/1-84628-009-5_11 · Cited by 1
Luizy, F. (2011) · Elsevier eBooks · doi:10.1016/b978-2-294-71346-0.50001-x · Cited by 1
Gender Issues in Venous Thromboembolism
Murin, S., Bilello, K. L., Moores, L. K., & Holley, A. B. (2010) · Principles of Gender-Specific Medicine · doi:10.1016/b978-0-12-374271-1.00020-4
Treatment of Acute Venous Thromboembolism in Hospitalized Patients
Minichiello, T., Doctoroff, L., & Farrell, E. A. (2011) · Wiley eBooks · doi:10.1002/9781118067178.ch7
Antiphospholipıd Syndrome and Venous Thrombosis
Okuyan, E. (2012) · InTech eBooks · doi:10.5772/27128
Vargas, G., & Alexandra, D. (2013) · Aaltodoc (Aalto University)
Chapter 18 The Antiphospholipid Syndrome
D’Cruz, D. P. (2007) · Technical report · doi:10.1016/s1571-5078(07)07018-3
Chapter 18 Difficult Clinical Situations in the Antiphospholipid Syndrome
Gordon, J., Goldenberg, D., Erkan, D., & Lockshin, M. D. (2009) · Technical report · doi:10.1016/s1571-5078(08)00418-2
Venous and arterial thrombosis : associations and risk factors
Roshani, S. (2012) · Leiden Repository (Leiden University)
Cryptogenic Emboli and Other Elusive Causes of Stroke
Smirnakis, S. M., & Koroshetz, W. J. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-769-7_13
Zasady leczenia wstępnego i wtórnej profilaktyki przeciwzakrzepowej w zatorze tętnicy płucnej
Kostrubiec, M., & Pruszczyk, P. (2010) · Via Medica Journals
Venous Thromboembolism: Gender Effects and Gender-Specific Risk Factors for Women
Murin, S., Moores, L. K., Bilello, K. L., & Matthay, R. A. (2004) · Principles of Gender-Specific Medicine · doi:10.1016/b978-012440905-7/50299-1
Bertolaccini, M. L., & Khamashta, M. A. (2010) · The Open Autoimmunity Journal · doi:10.2174/1876894601002020045
Treatment of the antiphospholipid antibody syndrome
Wu, C. W., & KALUNIAN, K. C. (2004) · Current Rheumatology Reports · doi:10.1007/s11926-004-0026-z
Comments on the Editorial “Antiphospholypid Syndrome: New Clinical and Therapeutic Perspectives”
Ruiz‐Irastorza, G., & Khamashta, M. A. (2007) · Reumatología Clínica (English Edition) · doi:10.1016/s2173-5743(07)70219-8
Wittkowsky, A. K. (2004) · Journal of Pharmacy Practice · doi:10.1177/0897190004272571
Tratamiento del síndrome antifosfolipídico en el embarazo
Villar, I., & Ruiz‐Irastorza, G. (2006) · Seminarios de la Fundación Española de Reumatología · doi:10.1016/s1577-3566(06)75081-3
Comentarios al editorial “Síndrome antifosfolipídico: nuevas perspectivas clínicas y terapéuticas”
Ruiz‐Irastorza, G., & Khamashta, M. A. (2007) · Reumatología Clínica · doi:10.1016/s1699-258x(07)73609-4
Lindhoff‐Last, E. (2008) · Journal of Laboratory Medicine · doi:10.1515/jlm.2008.036et
New insights into the management of antiphospholipid syndrome-related thrombosis
Puente, D., & Forastiero, R. R. (2008) · Future Rheumatology · doi:10.2217/17460816.3.1.85
Importance des anticorps antiphospholipides en clinique
HACHULLA, E. (2001) · Immuno-analyse & Biologie Spécialisée · doi:10.1016/s0923-2532(01)80061-2
Antiphospholipid antibodies in venous thromboembolism patients younger than 50 years old.
Halvani, A., Owlia, M. B., & Mehrpour, G. (2010) · Tanaffos: Journal of Respiratory Disease, Thoracic Surgery, Intensive Care and Tuberculosis
On Diagnostic Procedures in Pulmonary Embolism
Söderberg, M. (2008) · Figshare
Duration of Anticoagulant Treatment after VenousThromboembolism
Becattini, C., & Agnelli, G. (2003) · Pathophysiology of Haemostasis and Thrombosis · doi:10.1159/000083828
Lapidus, L. J. (2007) · Figshare
T HE A NTIPHOSPHOLIPID S YNDROME
Evine, S. L., Are, D. W., Ranch, B., & Auch, J. O. R. (2002)
Enquête étiologique au cours de la maladie veineuse thromboembolique
Delluc, A., Gal, G. L., & Mottier, D. (2010) · Encyclopédie médico-chirurgicale. Pneumologie · doi:10.1016/s1155-195x(10)47974-8
41 Management of Thrombocytopenia in
Syndrome, H., Galli, M., & Barbui, T. (2000)
de risco para o parto prematuro
Rades, É. (2007)
Yasuda, S. (2013) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.102.2621
Anticoagulation Therapy for the Antiphospholipid Syndrome
Goodnight, S. H. (2001) · CRC Press eBooks · doi:10.1201/9781420040395-44
Sasaki, R., Ito, K., Imafuku, S., & Yamaguchi, K. (2016) · The Nishinihon Journal of Dermatology · doi:10.2336/nishinihonhifu.78.121
Laboratory Testing for Antiphospholipid Syndrome
Ioannou, Y., & Krilis, S. A. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-374994-9.10052-x
Can Patients with Known Intracranial and Intraspinal Vascular Lesions Be Anticoagulated?
Robinson, C. P., Star, M., & Biller, J. (2016) · Springer eBooks · doi:10.1007/978-3-319-27327-3_26
Eular On-line Course on Rheumatic Diseases - module n°19
Khamashta, M. A., Bertolaccini, M. L., & Østensen, M. (2008)
Hypercoagulable Conditions Leading to Limb Ischemia
Jayaraj, A., Wysokiński, W. E., & McBane, R. D. (2016) · Springer eBooks · doi:10.1007/978-3-319-31991-9_25
Prognosis in Antiphospholipid Syndrome
Serrano, R. M., Pons‐Estel, G., Espinosa, G., & Cervera, R. (2016) · Technical report · doi:10.1016/b978-0-444-63655-3.00019-3
Prevention of recurrent thrombosis in antiphospholipid antibody syndrome
Windyga, J. (2004) · Via Medica Journals
Huang, W. (2014) · The Journal of the American Medical Association (JAMA) Network (American Medical Association) · doi:10.13028/m2j304
Fact checking the lore of hypercoagulable work up
Shen, Y.-M. P. (2017)
Quelles sont les particularités thérapeutiques au cours du syndrome des antiphospholipides ?
Benhamou, Y., Delluc, A., Am, F., & Sanchez, O. (2019) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2019.05.017
Veselinović, M., Lucic, A. T., Jakovljevic, V. L., & Aničić, A. (2019) · Medicinski casopis · doi:10.5937/mckg53-23292
Lim, W. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-397164-7.00104-x
Anticoagulation in the Perioperative Period
Suwanawiboon, B., & Ortel, T. L. (2007) · Elsevier eBooks · doi:10.1016/b978-141602401-9.10038-0
Thrombosis with Thrombocytopenia - A Vascular Paradox
Nanjappa, V., Devegowda, L., Rathore, A., Sadanand, K. S., & Nanjappa, M. C. (2020) · Journal of Evidence Based Medicine and Healthcare · doi:10.18410/jebmh/2020/634
Auer, K. (2003)
Linkins, L., & Kearon, C. (2009) · Wiley eBooks · doi:10.1002/9781444309768.ch64
Chandrasekar, T. S., Janakan, G. B., Viveksandeep, T. C., Kalamegam, R. Y., Suriyanarayanan, S., & Prasad, M. S. (2021) · Journal of Digestive Endoscopy · doi:10.1055/s-0040-1701397
Angeborene und erworbene Thrombophilien
Schneppenheim, R., Helmke, K., & Helmke, F. (2005) · Springer eBooks · doi:10.1007/3-540-29036-2_40
Dizon‐Townson, D. (2010) · Wiley eBooks · doi:10.1002/9781444316780.ch21
McRae, S. J. (2020) · Springer eBooks · doi:10.1007/978-3-030-43683-4_10
Kearon, C., Ginsberg, J. S., & Hirsh, J. (2002) · Wiley eBooks · doi:10.1002/9780470986882.ch61
Liebman, H. A., & Weitz, I. C. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5223-4.00037-8
Antiphospholipid Antibody Syndrome
Zambon, M., Cappelli, D., & Berlot, G. (2012) · Springer eBooks · doi:10.1007/978-88-470-2448-9_13
Clinical manifestations associated with the presence of antiphospholipid antibodies
Miljić, P., Bodrožić, J., & Vlajin, S. (2024) · Srpski medicinski casopis Lekarske komore · doi:10.5937/smclk5-52491
Antithrombotic Treatment in Antiphospholipid Syndrome: A Review
Siniscalchi, C., Bernardi, F. F., Micco, P. D., Perrella, A., Meschi, T., & Trama, U. (2024) · Immuno · doi:10.3390/immuno4040036 · Cited by 1
Papilledema and Venous Sinus Thrombosis
Muscente, J. (2024) · Springer eBooks · doi:10.1007/978-3-031-73467-0_22
Vitamin K Antagonists and Novel Oral Anticoagulant
Agnelli, G., & Becattini, C. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-287-8_14
Bourke, L. (2014) · UCL Discovery (University College London)
Yahia, S. H., Lazarov, H., Niznik, S., Shavit, R., Lubetsky, A., & Agmon-Levin, N. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.03.029
Identification de facteurs de risque de la maladie thrombo-embolique veineuse
Ibrahim, M. (2020) · theses.fr (ABES) · doi:10.70675/e799e289z7fc5z431eza6bfz81bb42ac753e
Duration of Anticoagulant Therapy After Venous Thromboembolism
Kearon, C. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-235-3_19
Metadata
- Authors
- Schulman, S., Svenungsson, E., & Granqvist, S.
- Affiliations
- Karolinska University Hospital (SE)
- Ersta sjukhus (SE)
- Corresponding author
- Schulman, Sam
- Venue
- The American Journal of Medicine
- Publisher
- Elsevier BV
- Published
- 1998-04
- Volume
- 104
- Issue
- 4
- Pages
- 332-338
- ISSN
- 0002-9343 (ISSN-L)
- OpenAlex
- W2152900444
- Cited by
- 497
- References
- 24
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 9 · 2023: 6 · 2022: 4 · 2021: 5 · 2020: 10 · 2019: 13 · 2018: 9 · 2017: 10 · 2016: 13 · 2015: 8 · 2014: 9 · 2013: 18 · 2012: 21
- FWCI
- 19.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The American Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Hjärt-Lungfonden
- Karolinska Institutet
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- anticardiolipin antibodies, antiphospholipid antibodies, venous thromboembolism, thromboembolism recurrence, oral anticoagulation, long-term anticoagulation, mortality, antibody titers, international normalized ratio
- MeSH terms
- Aged, Anticoagulants, Cause of Death, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prognosis, Recurrence, Risk, Thromboembolism, Antibodies, Anticardiolipin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
